MindMed to Participate in September Investor Conferences

MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced its participation in four major investor conferences in September 2025.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

• Cantor Global Healthcare Conference 2025
  • Format: Fireside Chat
  • Date and Time: Friday, September 5, 2025 at 10:55 AM ET
  • Location: New York, NY
  • Webcast Link: Cantor Global Healthcare Conference 2025
• H.C. Wainwright 27^th Annual Global Investment Conference
  • Format: Fireside Chat
  • Date and Time: Tuesday, September 9, 2025 at 3:30 PM ET
  • Location: New York, NY
  • Webcast Link: H.C. Wainwright 27th Annual Global Investment Conference
• Baird 2025 Global Healthcare Conference
  • Format: Fireside Chat
  • Date and Time: Wednesday, September 10, 2025 at 10:50 AM ET
  • Location: New York, NY
• TD Cowen’s 5^th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
  • Format: Fireside Chat
  • Date and Time: Thursday, September 18, 2025 at 1:00 PM ET
  • Location: Virtual
  • Webcast Link: TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.

About MindMed

MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250828038491/en/

For Media: media@mindmed.co
For Investors: ir@mindmed.co

Source: Mind Medicine Inc.